|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Department of Neuropsychiatry |
Mishima Kazuo
|
|
|
Research Interests 【 display / non-display 】
-
Sleep medicine
-
精神神経科学／時間生物学/分子遺伝学/睡眠/加齢変化/精神薬理学的研究
-
Psychiatry
-
Chronobiology
-
精神科学
Graduating School 【 display / non-display 】
-
-1987.03
Akita University Faculty of Medicine Graduated
Campus Career 【 display / non-display 】
-
2018.09-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Professor
Research Areas 【 display / non-display 】
-
Life Science / Neuroscience-general
-
Life Science / Psychiatry
-
Life Science / Neuroscience-general
Research Achievements 【 display / non-display 】
-
Identification of Factors to Predict Transition to Schizophrenia in Subjects with Ultra-high Risk for Psychosis: A Protocol for a Multicenter, Longitudinal Study of Sleep Parameters and Cytokine Levels.
Yuji Yamada, Kazuo Mishima, Takashi Ohnishi, Michio Suzuki, Takahiro Nemoto, Masafumi Mizuno, Toshifumi Kishimoto, Hiroaki Tomita, Motohiro Ozone, Shingo Kitamura, Kenji Hashimoto, Kazuyuki Nakagome, Tomiki Sumiyoshi
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 23 ( 2 ) 266 - 277 2025.05 [Refereed]
Research paper (journal) Domestic Co-author
OBJECTIVE: Schizophrenia is a major psychiatric illness which mostly begins in adolescence and leads to impairments of social functioning. Some patients with schizophrenia have been associated with ultra-high risk state for psychosis (UHR), a condition used to operationally represent the prodromal stage of the illness. In previous studies, the UHR and the progression to overt psychosis has been reported to be accompanied with alterations in the quality of sleep and the immune system, as represented by change of blood levels of cytokines. Currently, biomarkers to predict the development of psychosis in persons at UHR have not yet reached a steady consensus. Therefore, we present a study protocol to explore predictors of transitions to psychosis, in the realm of monitoring of sleep condition and cytokine measurement, in subjects with the UHR. METHODS: This is a multicenter, longitudinal cohort study participated by 7 hospitals in Japan. We will recruit 50 UHR people and 30 healthy volunteers as a control group, and measure positive symptom, depressive symptoms, cognitive function, and social function. Blood cytokines levels and sleep indices, as well as actigraphy data will be monitored. After the baseline assessment, clinical symptoms, sleep indices, and cytokine levels will be measured every 12 weeks for 52 weeks. Actigraphy devices will continue to be worn for 52 weeks, while social function will be assessed over 104 weeks. The results of this study are expected to facilitate the development of novel intervention therapies to reduce the risk of psychosis and improve functional outcomes.
-
Development, reliability, and validity of the quality of life scale for insomnia: a health-related quality of life instrument for insomnia.
Naoko Ayabe, Isa Okajima, Wataru Yamadera, Hisateru Tachimori, Hidehisa Yamashita, Naohisa Uchimura, Ken Inada, Yuichi Inoue, Kazuo Mishima
Frontiers in psychiatry 16 1538148 - 1538148 2025.05 [Refereed]
Research paper (journal) Domestic Co-author
BACKGROUND: Insomnia is a quality of life (QOL) disorder complicated by various mental or physical daytime dysfunctions in addition to nocturnal insomnia symptoms. This study aimed to develop and examine the reliability and validity of a self-administered scale that can sensitively and easily assess QOL disturbances in patients with insomnia. METHODS: From 122 patients with primary insomnia (mean age 53.8 ± 17.1 years), 11 items correlated with sleep-related clinical indices were extracted and designated the QOL Scale for insomnia (QOL-I). The QOL-I reliability and validity were evaluated. RESULTS: The analysis included 93 patients with chronic insomnia (mean age 54.2 ± 16.0 years) and 228 healthy participants (45.0 ± 15.7 years). The QOL-I showed high reliability (Cronbach α=0.92). Factor analysis showed that the QOL-I has a one-factor structure. Correlation analysis between the QOL-I and other variables indicated criterion-related validity (p<0.001). CONCLUSION: The QOL-I demonstrated good reliability and validity and is expected to be a valuable tool for clinically assessing the QOL of patients with insomnia.
-
Detection of sleep apnea using smartphone-embedded inertial measurement unit.
Junichiro Hayano, Masahiro Takeshima, Aya Imanishi, Masaya Ogasawara, Yasuko Yamada, Emi Yuda, Kazuo Mishima
Scientific reports 15 ( 1 ) 14923 - 14923 2025.04 [Refereed]
Research paper (journal) Domestic Co-author
We previously demonstrated that sleep apnea (SA) can be detected using acceleration and gyroscope signals from smartwatches. This study investigated whether an inertial measurement unit (IMU) embedded in non-wristwatch devices, such as smartphones, can also detect SA when worn during sleep. During polysomnography (PSG), subjects wore an IMU-embedded GPS device (Amue Link®) and/or smartphones (Xperia® or iPhone®) on their abdomen. Triaxial acceleration and gyroscope signals were recorded overnight. Data were split into training and test groups (2:1) for each device. An algorithm was developed in the training groups to extract respiratory movements (0.13-0.70 Hz) and detect respiratory events, which were validated in the test groups. IMU-derived respiratory events showed breath-by-breath concordance with PSG apnea-hypopnea events, yielding F1 scores of 0.786, 0.821, and 0.796, respectively. Regression model derived from IMU signals correlated with PSG AHI in the test groups (r = 0.90, 0.93, and 0.96), with limits of agreement of -16.7 to 25.9, -17.4 to 22.5, and - 18.4 to 20.5. Using cutoff values from the training groups, moderate-to-severe SA (AHI ≥ 15) was identified in the test groups with AUCs of 0.95, 0.98, and 0.94 and F1 scores of 0.89, 0.96, and 0.92, respectively. IMUs embedded in non-wristwatch devices, including smartphones, can quantitatively detect SA when worn during sleep.
-
Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies.
Makoto Uchiyama, Kazuo Mishima, Tomoko Yagi, Tatsuya Yoshihara, Takashi Eto, Clemens Muehlan, Osamu Togo, Yuichi Inoue
Journal of sleep research 34 ( 1 ) e14302 2025.02 [Refereed]
Research paper (journal) Domestic Co-author
Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia. We report results from the first two randomised, double-blind clinical studies of daridorexant in Japanese subjects. In the Phase 1 study, daridorexant (10, 25, 50 mg) or placebo were administered in the morning for 4 days in 24 young (mean age 26.9 years) and 24 older (mean age 69.7 years) healthy Japanese adults. Daridorexant reached a peak plasma concentration within 1.0 h across every dose and age group. For all doses, the mean plasma concentration of daridorexant showed a similar change between the age groups. Exposure parameters increased dose-dependently with minimal/no accumulation upon repeated dosing. The terminal half-life was ~8 h. In the Phase 2, four-period, four-way crossover study, 47 Japanese subjects (mean age 50.4 years) with insomnia disorder were randomised to receive four treatments (daridorexant 10, 25, 50 mg, placebo) during four treatment periods, each consisting of two treatment nights (5-12 day washout between treatment periods). Subjects continued their fourth treatment for 12 further days. A statistically significant dose-response relationship (multiple-comparison procedure-modelling, p < 0.0001) was found in the reduction of polysomnography-measured wake after sleep onset (WASO; primary endpoint) and latency to persistent sleep (secondary endpoint) from baseline to days 1/2. Statistically significant dose-response relationships were also observed for secondary subjective endpoints from baseline to days 1/2 (sWASO, latency to sleep onset). All daridorexant doses were well tolerated, with no treatment discontinuations and no next-morning residual effects. These results supported further investigation of daridorexant in Japanese patients with insomnia disorder.
-
Autoimmune Encephalitis in Psychiatry
筒井幸, 筒井幸, 筒井幸, 大森佑貴, 神林崇, 神林崇, 加藤倫紀, 嵯峨佑史, 三島和夫, 清水徹男, 加藤征夫, 田中惠子
精神神経学雑誌 126 ( 2 ) 2024.02
Introduction and explanation (scientific journal) Domestic Co-author
-
岸太郎, 江角悟, 大矢一登, 奥谷理, 佐久間健二, 野村郁雄, 橋本保彦, 波多野正和, 波多野正和, 松井佑樹, 松田勇紀, 三宅誕実, 三島和夫, 岩田仲生
臨床精神薬理 24 ( 9 ) 937 - 942 2021
Introduction and explanation (scientific journal) Domestic Co-author
-
How to use, reduce, and stop hypnotics after insomnia remission
22 ( 8 ) 815 - 820 2019.08
Introduction and explanation (scientific journal)
-
Non-visual Effects of Light : Influence on alertness and cognitive function
61 ( 8 ) 883 - 889 2019.08
Introduction and explanation (scientific journal)
-
【知っておきたい器質性・症状性・薬剤性の精神障害:Update】抗NMDA受容体脳炎
筒井 幸, 馬越 秋瀬, 神林 崇, 田中 惠子, 清水 徹男, 三島 和夫
臨床精神医学 ( (株)アークメディア ) 48 ( 1 ) 11 - 16 2019.01
Introduction and explanation (scientific journal)
-
Establishment and management of a polysomnography databank for sleep disorders in Japan
河村葵, 松井健太郎, 吉池卓也, 木村綾乃, 都留あゆみ, 長尾賢太朗, 木附隼, 内海智博, 伊豆原宗人, 岡邨しのぶ, 伏見もも, 北村真吾, 竹島正浩, 岩本邦弘, 角谷寛, 鈴木正泰, 小曽根基裕, 三島和夫, 井上雄一, 栗山健一
日本生物学的精神医学会(Web) 45th 2023.11
Summary of the papers read (national conference and other science council) Domestic Co-author
-
Association of stay-home order during COVID-19 pandemic with depressive symptoms and suicide-related ideation in university students in Japan
野村恭子, 南園佐知子, 前田恵理, KIM Roseline, 岩田豊人, 平山純子, 尾野恭一, 伏見雅人, 後藤猛, 三島和夫, 山本文雄
日本心身医学会総会ならびに学術講演会抄録集 62nd (CD-ROM) 2021
Summary of the papers read (national conference and other science council) Domestic Co-author
-
睡眠・覚醒相後退障害に対する心理社会支援プログラム開発の試み
綾部直子, 吉村道孝, 栗山健一, 三島和夫, 三島和夫
日本睡眠環境学会学術大会抄録集 28th 106 2019.09
Summary of the papers read (national conference and other science council)
-
精神科学と神経免疫学のクロストーク 精神科領域からみた自己免疫性辺縁系脳炎
筒井 幸, 馬越 秋瀬, 奥口 悠紀, 神林 崇, 田中 惠子, 清水 徹男, 三島 和夫
精神神経学雑誌 ( (公社)日本精神神経学会 ) ( 2019特別号 ) S340 - S340 2019.06
Summary of the papers read (national conference and other science council)
-
北村真吾, 榎本みのり, 三井寺浩幸, 立森久照, 三島和夫
国立精神・神経医療研究センター精神保健研究所年報 ( 30 ) 235 2017.10
Summary of the papers read (national conference and other science council)
◆Original paper【 display / non-display 】
◆Introduction and explanation【 display / non-display 】
◆Other【 display / non-display 】
Books 【 display / non-display 】
-
Tasman’s Psychiatry
三島和夫
Springer 2023.01
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2023.04 - 2027.03
-
Construction and feature analysis of a model for predicting clinical outcomes of psychiatric disorders using sleep, behavioral, and physiological parameters.
Grant-in-Aid for Scientific Research(B)
Project Year： 2022.04 - 2025.03
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2019.04 - 2022.03
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2016.04 - 2019.03
-
Grant-in-Aid for Scientific Research(S)
Project Year： 2015.04 - 2016.03
Presentations 【 display / non-display 】
-
A descriptive epidemiological study of pediatric sleep medications in Japan: a health insurance claims-based analysis
Fujimoto, K. Tanaka, S. Mishima, K. Sakata, Y. Kubota, N. Koebisu, M. Fukasawa,T. Mizuno, K. Ishii, M. Moline, M. Kawakami, K.
The ISPOR Europe 2024 conference (Barcelona, Spain) 2024.11 - 2024.11
-
Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics
Masahiro Takeshima, Kazuhisa Yoshizawa, Masaya Ogasawara, Yu Itoh, Kazuo Mishima
35th WORLD CONGRESS World Congress Collegium Internationale Neuro-Psychopharmacologicum (Tokyo) 2024.05 - 2024.05
-
Safety and Efficacy of Lemborexant in Patients with Insomnia Disorder: Report from a Post-marketing Observational Study
Kazuo Mishima1 Kenichi Fujimoto, Akira Endo,Mika Ishi
35th WORLD CONGRESS World Congress Collegium Internationale Neuro-Psychopharmacologicum (Tokyo) 2024.05 - 2024.05
Academic Activity 【 display / non-display 】
-
2020.10-Now
-
2020.10-Now
-
2020.03-Now